Summus-affiliated physician discusses the latest in HER2-positive breast cancer

By Summus | August 28, 2017

Mark Pegram, MD, recently spoke with OncLive about developments and the future of HER2-positive breast cancer. Dr. Pegram, a member of the Summus physician network, is director of the Stanford Breast Oncology Program and associate director for clinical research at the Stanford Cancer Institute.

Read Dr. Pegram’s interview with OncLive here.

About Summus

Summus informs medical decisions through fast, direct access to the world's best medical expertise. Our platform empowers families through navigation support and on-demand access to leading specialists across 48 leading hospitals - within days, from anywhere in the world.

Join Our Mailing List

Email Address
Please enter a valid email address.
Thank you for your interest in Summus.

Connect With Us